Cargando…
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
BACKGROUND: From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and ravulizumab, a monoclonal...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682367/ https://www.ncbi.nlm.nih.gov/pubmed/37977159 http://dx.doi.org/10.1016/S2213-2600(23)00376-4 |
_version_ | 1785150959573270528 |
---|---|
author | Hall, Frances C Cheriyan, Joseph Cope, Andrew P Galloway, James Wilkinson, Ian Bond, Simon Norton, Sam Banham-Hall, Edward Bayes, Hannah Kostapanos, Michalis Nodale, Marianna Petchey, William G Sheeran, Thomas Underwood, Jonathan Jayne, David R |
author_facet | Hall, Frances C Cheriyan, Joseph Cope, Andrew P Galloway, James Wilkinson, Ian Bond, Simon Norton, Sam Banham-Hall, Edward Bayes, Hannah Kostapanos, Michalis Nodale, Marianna Petchey, William G Sheeran, Thomas Underwood, Jonathan Jayne, David R |
author_sort | Hall, Frances C |
collection | PubMed |
description | BACKGROUND: From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and ravulizumab, a monoclonal inhibitor of complement C5 activation, as an adjunct to standard of care for the treatment of adult patients hospitalised with COVID-19. METHODS: TACTIC-R was a phase 4, randomised, parallel-arm, open-label platform trial that was undertaken in the UK with urgent public health designation to assess the potential of repurposing immunosuppressants for the treatment of severe COVID-19, stratified by a risk score. Adult participants (aged ≥18 years) were enrolled from 22 hospitals across the UK. Patients with a risk score indicating a 40% risk of admission to an intensive care unit or death were randomly assigned 1:1:1 to standard of care alone, standard of care with baricitinib, or standard of care with ravulizumab. The composite primary outcome was the time from randomisation to incidence (up to and including day 14) of the first event of death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure. The primary interim analysis was triggered when 125 patient datasets were available up to day 14 in each study group and we included in the analysis all participants who were randomly assigned. The trial was registered on ClinicalTrials.gov (NCT04390464). FINDINGS: Between May 8, 2020, and May 7, 2021, 417 participants were recruited and randomly assigned to standard of care alone (145 patients), baricitinib (137 patients), or ravulizumab (135 patients). Only 54 (39%) of 137 patients in the baricitinib group received the maximum 14-day course, whereas 132 (98%) of 135 patients in the ravulizumab group received the intended dose. The trial was stopped after the primary interim analysis on grounds of futility. The estimated hazard ratio (HR) for reaching the composite primary endpoint was 1·11 (95% CI 0·62–1·99) for patients on baricitinib compared with standard of care alone, and 1·53 (0·88–2·67) for ravulizumab compared with standard of care alone. 45 serious adverse events (21 deaths) were reported in the standard-of-care group, 57 (24 deaths) in the baricitinib group, and 60 (18 deaths) in the ravulizumab group. INTERPRETATION: Neither baricitinib nor ravulizumab, as administered in this study, was effective in reducing disease severity in patients selected for severe COVID-19. Safety was similar between treatments and standard of care. The short period of dosing with baricitinib might explain the discrepancy between our findings and those of other trials. The therapeutic potential of targeting complement C5 activation product C5a, rather than the cleavage of C5, warrants further evaluation. FUNDING: UK Medical Research Council, UK National Institute for Health Research Cambridge Biomedical Research Centre, Eli Lilly and Company, Alexion Pharmaceuticals, and Addenbrooke's Charitable Trust. |
format | Online Article Text |
id | pubmed-10682367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106823672023-12-01 Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial Hall, Frances C Cheriyan, Joseph Cope, Andrew P Galloway, James Wilkinson, Ian Bond, Simon Norton, Sam Banham-Hall, Edward Bayes, Hannah Kostapanos, Michalis Nodale, Marianna Petchey, William G Sheeran, Thomas Underwood, Jonathan Jayne, David R Lancet Respir Med Articles BACKGROUND: From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and ravulizumab, a monoclonal inhibitor of complement C5 activation, as an adjunct to standard of care for the treatment of adult patients hospitalised with COVID-19. METHODS: TACTIC-R was a phase 4, randomised, parallel-arm, open-label platform trial that was undertaken in the UK with urgent public health designation to assess the potential of repurposing immunosuppressants for the treatment of severe COVID-19, stratified by a risk score. Adult participants (aged ≥18 years) were enrolled from 22 hospitals across the UK. Patients with a risk score indicating a 40% risk of admission to an intensive care unit or death were randomly assigned 1:1:1 to standard of care alone, standard of care with baricitinib, or standard of care with ravulizumab. The composite primary outcome was the time from randomisation to incidence (up to and including day 14) of the first event of death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure. The primary interim analysis was triggered when 125 patient datasets were available up to day 14 in each study group and we included in the analysis all participants who were randomly assigned. The trial was registered on ClinicalTrials.gov (NCT04390464). FINDINGS: Between May 8, 2020, and May 7, 2021, 417 participants were recruited and randomly assigned to standard of care alone (145 patients), baricitinib (137 patients), or ravulizumab (135 patients). Only 54 (39%) of 137 patients in the baricitinib group received the maximum 14-day course, whereas 132 (98%) of 135 patients in the ravulizumab group received the intended dose. The trial was stopped after the primary interim analysis on grounds of futility. The estimated hazard ratio (HR) for reaching the composite primary endpoint was 1·11 (95% CI 0·62–1·99) for patients on baricitinib compared with standard of care alone, and 1·53 (0·88–2·67) for ravulizumab compared with standard of care alone. 45 serious adverse events (21 deaths) were reported in the standard-of-care group, 57 (24 deaths) in the baricitinib group, and 60 (18 deaths) in the ravulizumab group. INTERPRETATION: Neither baricitinib nor ravulizumab, as administered in this study, was effective in reducing disease severity in patients selected for severe COVID-19. Safety was similar between treatments and standard of care. The short period of dosing with baricitinib might explain the discrepancy between our findings and those of other trials. The therapeutic potential of targeting complement C5 activation product C5a, rather than the cleavage of C5, warrants further evaluation. FUNDING: UK Medical Research Council, UK National Institute for Health Research Cambridge Biomedical Research Centre, Eli Lilly and Company, Alexion Pharmaceuticals, and Addenbrooke's Charitable Trust. Elsevier 2023-12 /pmc/articles/PMC10682367/ /pubmed/37977159 http://dx.doi.org/10.1016/S2213-2600(23)00376-4 Text en © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Hall, Frances C Cheriyan, Joseph Cope, Andrew P Galloway, James Wilkinson, Ian Bond, Simon Norton, Sam Banham-Hall, Edward Bayes, Hannah Kostapanos, Michalis Nodale, Marianna Petchey, William G Sheeran, Thomas Underwood, Jonathan Jayne, David R Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial |
title | Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial |
title_full | Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial |
title_fullStr | Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial |
title_full_unstemmed | Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial |
title_short | Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial |
title_sort | efficacy and safety of baricitinib or ravulizumab in adult patients with severe covid-19 (tactic-r): a randomised, parallel-arm, open-label, phase 4 trial |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682367/ https://www.ncbi.nlm.nih.gov/pubmed/37977159 http://dx.doi.org/10.1016/S2213-2600(23)00376-4 |
work_keys_str_mv | AT hallfrancesc efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT cheriyanjoseph efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT copeandrewp efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT gallowayjames efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT wilkinsonian efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT bondsimon efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT nortonsam efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT banhamhalledward efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT bayeshannah efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT kostapanosmichalis efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT nodalemarianna efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT petcheywilliamg efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT sheeranthomas efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT underwoodjonathan efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT jaynedavidr efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial AT efficacyandsafetyofbaricitiniborravulizumabinadultpatientswithseverecovid19tacticrarandomisedparallelarmopenlabelphase4trial |